EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Multizentrische Studie

Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results

Dan Turner, Joel R Rosh, Stanley A Cohen, Anne M Griffiths, Jeffrey S Hyams, Jarosław Kierkuś, Omoniyi J Adedokun, Richard Strauss, Lilianne Kim, Sheri Volger, UniStar Study Group

Journal of Pediatric Gastroenterology and Nutrition · 2024-08 · 79 (2) · 315-324

DOI: 10.1002/jpn3.12252 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 27.05.2024. Verfasst von Dan Turner und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Juliet Keidan Institute of Paediatirc Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem,…. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Janssen Research & Development, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the efficacy, safety, immunogenicity, and pharmacokinetics through 240 weeks of ustekinumab treatment in paediatric patients from the long‐term extension (LTE) of the phase 1, double‐blind UniStar trial.

Methods

Paediatric patients with moderately to severely active Crohn's disease (CD) were randomised 1:1 and stratified by body weight (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseHumansMaleFemaleChildAdolescentDouble-Blind MethodTreatment OutcomeSeverity of Illness IndexRemission InductionC-Reactive Protein

Stichwörter der Autor:innen

Crohn's disease (CD)biologicsinflammatory bowel disease (IBD)paediatric gastroenterology

Substanzen

UstekinumabC-Reactive Protein

Autor:innen und Institutionen

  • The Juliet Keidan Institute of Paediatirc Gastroenterology and Nutrition, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Pediatric Gastroenterology, The Steven and Alexandra Cohen Children's Medical Center of New York, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, USA.
  • Pediatric Gastroenterology, Morehouse School of Medicine, Atlanta, Georgia, USA.
  • Pediatric Gastroenterology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Pediatric Gastroenterology, Connecticut Children's Medical Center, Hartford, Connecticut, USA.
  • Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Children's Memorial Health Institute, Warsaw, Poland.

Förderung

  • Janssen Research & Development, LLC

Zitieren

APA

Turner, D., Rosh, J. R., Cohen, S. A., Griffiths, A. M., Hyams, J. S., Kierkuś, J., Adedokun, O. J., Strauss, R., Kim, L., Volger, S., & UniStar Study Group (2024). Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results. Journal of Pediatric Gastroenterology and Nutrition, 79(2), 315-324. https://doi.org/10.1002/jpn3.12252

Vancouver

Turner D, Rosh JR, Cohen SA, Griffiths AM, Hyams JS, Kierkuś J, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results. Journal of Pediatric Gastroenterology and Nutrition. 2024;79(2):315-324. doi:10.1002/jpn3.12252

BibTeX
@article{Turner2024,
  author = {Turner, Dan and Rosh, Joel R and Cohen, Stanley A and Griffiths, Anne M and Hyams, Jeffrey S and Kierkuś, Jarosław and Adedokun, Omoniyi J and Strauss, Richard and Kim, Lilianne and Volger, Sheri and UniStar Study Group, UniStar Study Group},
  title = {Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  volume = {79},
  number = {2},
  pages = {315--324},
  doi = {10.1002/jpn3.12252}
}
Kostenlos starten →